Institute of Pharmaceutical Science, School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London SE1 9NH, United Kingdom.
Eur J Pharm Biopharm. 2020 Oct;155:128-138. doi: 10.1016/j.ejpb.2020.08.017. Epub 2020 Aug 25.
Inflammatory bowel disease (IBD) is a chronic and progressive disorder with destructive inflammation in the gastrointestinal tract (GIT). Biologics have changed the management of IBD, but have serious limitations, which is associated with their systemic administration via injection. Oral administration is the most accepted route of drug administration. However, the physiological barriers of the GIT pose significant challenges for oral administration of biologics, making this route of administration currently unavailable. The status of tissue barriers to oral drug delivery is altered in IBD. This may bring more challenges, but also present opportunities for oral delivery of biologics. This article provides an overview of disease-induced alterations of GIT barriers in IBD and discusses challenges, opportunities and commonly-utilised strategies for oral delivery of complex therapeutics, including biologics and nanomedicines.
炎症性肠病（IBD）是一种慢性且进行性的疾病，胃肠道（GIT）存在破坏性炎症。生物制剂改变了 IBD 的治疗方式，但存在严重的局限性，这与其通过注射进行全身给药有关。口服给药是最被接受的药物给药途径。然而，GIT 的生理屏障给生物制剂的口服给药带来了巨大的挑战，使得这种给药途径目前无法实现。IBD 会改变组织屏障对口服药物输送的状态。这可能会带来更多的挑战，但也为生物制剂的口服给药带来了机会。本文概述了 IBD 中 GIT 屏障的疾病诱导改变，并讨论了口服输送复杂治疗药物（包括生物制剂和纳米药物）的挑战、机遇和常用策略。
